Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia

• Sponsor: Siami, Paul F., M.D. (Other)
• Overall Status: Completed
• CT.gov ID: NCT00701779
• Collaborator: GlaxoSmithKline (Industry)
• Enrollment: 63
• Location: 1
• Arm: 1
• Duration (Months): 46
• Patients Per Site Per Month: 1.4

Study Details

Study Description

Brief Summary

This study will investigate the efficacy and safety of treatment with Dutasteride (0.5mg), administered once daily for one year in combination with Tamsulosin (0.4mg), administered once daily for 3 months, followed by counseling on flexible dosing of Tamsulosin on an as needed basis, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia (BPH). At each scheduled visit (3, 6, and 9 months), the subject will be counseled on withdrawal of Tamsulosin. After randomization, study visits are every 13 weeks for up to 52 Weeks. (Including Screening, (up to 7 clinic visits)

Condition or Disease	Intervention/Treatment	Phase
Benign Prostatic Hyperplasia	Drug: Tamsulosin	Phase 4

Detailed Description

This study will investigate the efficacy and safety of treatment with Dutasteride (0.5mg), administered once daily for one year in combination with Tamsulosin (0.4mg), administered once daily for 3 months, followed by counseling on flexible dosing of Tamsulosin on an as needed basis, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia (BPH). At each scheduled visit (3, 6, and 9 months), the subject will be counseled on withdrawal of Tamsulosin.

A recently published, landmark study (MTOPS - Medical Therapy of Prostatic Symptoms), co-sponsored by the National Institute of Health and the National Institute of Diabetes, Digestive and Kidney Diseases (NIH-NIDDK), demonstrated that, in selected patients, combination therapy with Doxazosin and Finasteride provided additive symptomatic improvements, reduced the risk of acute urinary retention (AUR) and surgical intervention, and was a more effective treatment for reduction in the overall risk of BPH clinical progression.

The aim of this proposed combination study, in a population of patients at high risk of BPH clinical progression, is to investigate whether combination therapy with Dutasteride and Tamsulosin with the subsequent withdrawal of Tamsulosin can maintain superior symptom improvement. At each scheduled visit (3, 6, and 9 months), the subject will be counseled on withdrawal of Tamsulosin. We hypothesize that patients may start with a combination of Dutasteride and Tamsulosin and eventually may be able to eliminate the use of Tamsulosin and maintain acceptable urinary symptoms on Dutasteride alone.

Study Design

• Study Type: Interventional
• Actual Enrollment: 63 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH
• Study Start Date: Sep 1, 2005
• Actual Primary Completion Date: Jul 1, 2009
• Actual Study Completion Date: Jul 1, 2009

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Dutasteride Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks.

Drug: Tamsulosin; Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.; Other Names: Flomax

Outcome Measures

Primary Outcome Measures

1. International Prostate Symptom Score [12 months]

   Reported mean total IPSS values from end of study (12 month visit) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients. Questionnaire consisting of seven symptom scores: incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Symptoms are scored on a 5 point scale with 0 representing absence of symptoms and 5 representing the most severe presentation of a symptom. Total range is from 0-35. The scores are evaluated as such: 0-7: Mild 8-19: Moderate 20-35: Severe

2. Peak Flow Rate (QMax) [12 months]

   Peak flow rate recorded at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients.

3. Benign Prostate Hyperplasia Impact Index [12 months]

   Benign prostate hyperplasia Impact Index obtained at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients. Benign Prostatic Hyperplasia Impact Index asked the following: Over the past month, how much physical discomfort did any urinary problems cause you? (0-3) Over the past month, how much did you worry about yoru health because of any urinary problems? (0-3) Overall, how bothersome has any trouble with urination been during the past month? (0-3) Over the past month, how much of the time has any urinary problem kept you from doing the kinds of things you usually do? (0-4) 0 indicates no symptoms, high values indicate high frequency of symptoms. Total symptom score range 0-13.

4. Post-void Residual Volume [12 months]

   Post-void residual volume taken at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients.

5. Prostate Specific Antigen [12 months]

   Prostate Specific Antigen (PSA) taken at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients.

Secondary Outcome Measures

1. Health Outcome Measures [13 months]

   Number of participants who are able to subsequently reduce or discontinue Tamsulosin usage after starting with combination therapy with Dutasteride and Tamsulosin while still maintaining the same degree of improvement in lower urinary tract symptoms

2. Safety and Tolerability [13 months]

   To assess safety and tolerability of starting with combination therapy with Dutasteride and Tamsulosin and subsequent elimination of Tamsulosin. Evaluating number of reported adverse events designated as possibly or probably study-drug related.

3. Economic Impact [13 months]

   Annual financial cost per participant starting with combination therapy with Dutasteride and Tamsulosin with subsequent withdrawal of Tamsulosin.

4. Number of Participants With a Reduction of AUR and BPH-related Surgery [13 months]

   To assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior improvement in the clinical outcomes of AUR or BPH-related prostatic surgery to BPH patients.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 50 Years and Older
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Male ≥50 yrs

2. Diagnosed BPH by medical history and physical examination, including a digital rectal examination

3. International Prostate Symptom Score ≥12 points at Screening

4. Prostate volume ≥30cc (by transrectal ultrasonography; TRUS)

5. Total serum Prostate Specific Antigen ≥1.5 ng/mL at Screening

6. Maximum flow rate ≥5 mL/sec and ≤15 mL/sec and minimum voided volume of ≥125 mL at Screening (based on two voids)

7. Able to give written informed consent and comply with study procedures

8. Literate in English language with the ability to read, comprehend, and record information on the IPSS, BII, and PPSM questionnaires

9. Able to swallow and retain oral medication

10. Able to participate for study duration

Exclusion Criteria:

1. Total serum PSA >10.0 ng/mL at Screening. Patients with total serum PSA >10.0 ng/mL may be acceptable for inclusion if the PSA elevation is thought to be due to BPH and not prostate cancer (by TRUS and biopsies showing no evidence of prostate cancer).

2. History or evidence of prostate cancer

3. Previous prostatic surgery or other invasive procedures to treat BPH

4. History of flexible/rigid cystoscopy or other instrumentation of the urethra within 7 days prior to Screening. Catheterization (<10F) is acceptable with no time restriction.

5. History of AUR within 3 months prior to Screening

6. Post-void residual volume >250mL (suprapubic ultrasound) at Screening

7. Any causes other than BPH, which may in the judgment of the investigator, result in urinary symptoms or changes in flow rate

8. History of breast cancer or clinical breast examination finding of unclear origin or suggestive of malignancy

9. Use of 5 alpha-reductase inhibitor, any drugs with antiandrogenic properties, or drugs noted for gynecomastia effects, within past 6 months and throughout the study. Previous use of AVODART within 12 months of the baseline or historical TRUS. Chronic use of Metronidazole is prohibited.

10. Concurrent use of anabolic steroids

11. Use of phytotherapy for BPH within 2 weeks of Screening

12. Use of any alpha-adrenoreceptor blockers within 2 weeks of Screening

13. Use of any alpha-adrenoreceptor agonists, anticholinergics or cholinergics within 48 hours prior to all uroflowmetry assessments.

14. Hypersensitivity to any alpha-/beta- adrenoreceptor blocker or 5-alpha-reductase inhibitor, or other chemically-related drugs.

15. Concurrent use of drugs known or thought to interaction with Tamsulosin.

16. History of hepatic impairment, abnormal liver function at Screening, History of renal insufficiency, serum creatinine >1.5 times the upper limit

17. history of malignancies other than basal cell carcinoma or squamous cell carcinoma of the skin within the past 2 years.

18. History of any illness the investigator might confound the results of the study or poses additional risk to the patient.

19. Any unstable, serious co-existing medical condition(s) 21. History of postural hypotension, dizziness, vertigo, or any other signs and symptoms of orthostasis.

20. History of 'first dose' hypotensive episode on initiation of alpha-l-adrenoreceptor antagonist therapy.

21. History of unsuccessful treatment with finasteride or Dutasteride 24. History or current drug or alcohol abuse within the previous 12 months. 25. Participation in any investigational or marketed drug trial within 30 days (or 5 half-lives whichever is the longer) preceding Screening and/or during the course of this study.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Institute of Deaconess Clinic	Evansville	Indiana	United States	47713

Sponsors and Collaborators

• Siami, Paul F., M.D.
• GlaxoSmithKline

Investigators

• Principal Investigator: Paul F Siami, MD, Deaconess Clinic Research Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Paul F. Siami, MD, Medical Director, Research Institute of Deaconess Clinic, Siami, Paul F., M.D.
• ClinicalTrials.gov Identifier: NCT00701779
• Other Study ID Numbers: Siami104907
• First Posted: Jun 19, 2008
• Last Update Posted: Nov 2, 2018
• Last Verified: Nov 1, 2018

• Keywords provided by Paul F. Siami, MD, Medical Director, Research Institute of Deaconess Clinic, Siami, Paul F., M.D.: Benign Prostatic Hyperplasia; Dutasteride; Tamsulosin
• Additional relevant MeSH terms: Prostatic Hyperplasia; Hyperplasia; Tamsulosin

Study Results

Participant Flow

Recruitment Details	Medical Clinic
Pre-assignment Detail	The population of subjects will be the 'Intent-toTreat' population.

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Period Title: Overall Study
STARTED	63
3 Month	60
6 Month	58
9 Month	56
12 Month	54
COMPLETED	54
NOT COMPLETED	9

Baseline Characteristics

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Overall Participants	54
Age, Customized (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	66.63 (8.50)
Sex/Gender, Customized (participants) [Number]
Male	54 100%
International Prostate Symptom Score (IPSS) (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	19.80 (5.86)
Peak Flow Rate (ml/sec) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ml/sec]	10.14 (2.64)
Prostate Specific Antigen (ng/mL) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ng/mL]	4.70 (3.01)
Prostate Volume (cc) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [cc]	57.61 (22.83)
Post-Void Residual Volume (ml) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [ml]	82.33 (58.36)
Benign Prostatic Hyperplasia Impact Index (BII) (units on a scale) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [units on a scale]	6.31 (3.11)

Outcome Measures

1. Primary Outcome

Title	International Prostate Symptom Score
Description	Reported mean total IPSS values from end of study (12 month visit) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients. Questionnaire consisting of seven symptom scores: incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Symptoms are scored on a 5 point scale with 0 representing absence of symptoms and 5 representing the most severe presentation of a symptom. Total range is from 0-35. The scores are evaluated as such: 0-7: Mild 8-19: Moderate 20-35: Severe
Time Frame	12 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Mean (Standard Deviation) [units on a scale]	11.31 (6.48)

2. Primary Outcome

Title	Peak Flow Rate (QMax)
Description	Peak flow rate recorded at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients.
Time Frame	12 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Mean (Standard Deviation) [ml/sec]	20.43 (38.68)

3. Primary Outcome

Title	Benign Prostate Hyperplasia Impact Index
Description	Benign prostate hyperplasia Impact Index obtained at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients. Benign Prostatic Hyperplasia Impact Index asked the following: Over the past month, how much physical discomfort did any urinary problems cause you? (0-3) Over the past month, how much did you worry about yoru health because of any urinary problems? (0-3) Overall, how bothersome has any trouble with urination been during the past month? (0-3) Over the past month, how much of the time has any urinary problem kept you from doing the kinds of things you usually do? (0-4) 0 indicates no symptoms, high values indicate high frequency of symptoms. Total symptom score range 0-13.
Time Frame	12 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Mean (Standard Deviation) [units on a scale]	3.28 (2.81)

4. Primary Outcome

Title	Post-void Residual Volume
Description	Post-void residual volume taken at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients.
Time Frame	12 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Mean (Standard Deviation) [mL]	87.19 (83.47)

5. Primary Outcome

Title	Prostate Specific Antigen
Description	Prostate Specific Antigen (PSA) taken at final study visit (12 month) to assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior symptomatic improvement to BPH patients.
Time Frame	12 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Mean (Standard Deviation) [ng/mL]	1.91 (1.52)

6. Secondary Outcome

Title	Health Outcome Measures
Description	Number of participants who are able to subsequently reduce or discontinue Tamsulosin usage after starting with combination therapy with Dutasteride and Tamsulosin while still maintaining the same degree of improvement in lower urinary tract symptoms
Time Frame	13 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Count of Participants [Participants]	31 57.4%

7. Secondary Outcome

Title	Safety and Tolerability
Description	To assess safety and tolerability of starting with combination therapy with Dutasteride and Tamsulosin and subsequent elimination of Tamsulosin. Evaluating number of reported adverse events designated as possibly or probably study-drug related.
Time Frame	13 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Number [adverse events]	27

8. Secondary Outcome

Title	Economic Impact
Description	Annual financial cost per participant starting with combination therapy with Dutasteride and Tamsulosin with subsequent withdrawal of Tamsulosin.
Time Frame	13 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Mean (Standard Deviation) [US dollars]	643.99 (306.91)

9. Secondary Outcome

Title	Number of Participants With a Reduction of AUR and BPH-related Surgery
Description	To assess efficacy of starting with combination treatment with Dutasteride for one year and Tamsulosin for 3 months with subsequent as needed use of Tamsulosin in providing superior improvement in the clinical outcomes of AUR or BPH-related prostatic surgery to BPH patients.
Time Frame	13 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Measure Participants	54
Count of Participants [Participants]	54 100%

Adverse Events

Arm/Group Title	Dutasteride
Arm/Group Description	Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis. Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks. Tamsulosin: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
All Cause Mortality
	Dutasteride
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Dutasteride
	Affected / at Risk (%)	# Events
Total	6/63 (9.5%)
Blood and lymphatic system disorders
Pancytopenia	1/63 (1.6%)	1
Cardiac disorders
Chest Pain	3/63 (4.8%)	3
Atrial Fibrillation	1/63 (1.6%)	1
Bradycardia	1/63 (1.6%)	1
Musculoskeletal and connective tissue disorders
Osteoarthritis worsening	1/63 (1.6%)	1
Respiratory, thoracic and mediastinal disorders
Shortness of Breath	1/63 (1.6%)	1
Acute Bronchitis	1/63 (1.6%)	1
Pneumonia	1/63 (1.6%)	1
Vascular disorders
Cerebrovascular Accident	1/63 (1.6%)	1
Deep Vein Thrombosis	1/63 (1.6%)	1
Peripheral Vascular Disease	1/63 (1.6%)	1
Other (Not Including Serious) Adverse Events
	Dutasteride
	Affected / at Risk (%)	# Events
Total	27/63 (42.9%)
Gastrointestinal disorders
Lower Abdominal Pain	4/63 (6.3%)	4
General disorders
Fatigue	3/63 (4.8%)	3
Injury, poisoning and procedural complications
Laceration	3/63 (4.8%)	3
Musculoskeletal and connective tissue disorders
Back Pain	4/63 (6.3%)	4
Reproductive system and breast disorders
Retrograde Ejaculation	8/63 (12.7%)	9
Respiratory, thoracic and mediastinal disorders
Bronchitis	4/63 (6.3%)	5
Cough	7/63 (11.1%)	7
Sinus Infection	4/63 (6.3%)	4
Skin and subcutaneous tissue disorders
Rash	4/63 (6.3%)	4

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.